Chandra Bhagat Pharma (BOM:542934) Debt-to-EBITDA : 4.37 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Chandra Bhagat Pharma Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Chandra Bhagat Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹132 Mil. Chandra Bhagat Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹44 Mil. Chandra Bhagat Pharma's annualized EBITDA for the quarter that ended in Sep. 2023 was ₹40 Mil. Chandra Bhagat Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 4.37.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Chandra Bhagat Pharma's Debt-to-EBITDA or its related term are showing as below:

BOM:542934' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 4.58 Med: 5.5 Max: 8.61
Current: 4.58

During the past 7 years, the highest Debt-to-EBITDA Ratio of Chandra Bhagat Pharma was 8.61. The lowest was 4.58. And the median was 5.50.

BOM:542934's Debt-to-EBITDA is ranked worse than
78.78% of 655 companies
in the Drug Manufacturers industry
Industry Median: 1.66 vs BOM:542934: 4.58

Chandra Bhagat Pharma Debt-to-EBITDA Historical Data

The historical data trend for Chandra Bhagat Pharma's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chandra Bhagat Pharma Debt-to-EBITDA Chart

Chandra Bhagat Pharma Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

Get a 7-Day Free Trial

6.98

8.61

7.00

5.13

5.50

Chandra Bhagat Pharma Semi-Annual Data
	Mar17	Mar18	Mar19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial						6.07	5.09	6.28	5.21	4.37

Competitive Comparison of Chandra Bhagat Pharma's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Chandra Bhagat Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chandra Bhagat Pharma's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chandra Bhagat Pharma's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Chandra Bhagat Pharma's Debt-to-EBITDA falls into.

Chandra Bhagat Pharma Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Chandra Bhagat Pharma's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(150.171	+	39.276)	/	34.477
	=	5.49

Chandra Bhagat Pharma's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(131.832	+	43.621)	/	40.158
	=	4.37

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Chandra Bhagat Pharma (BOM:542934) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Chandra Bhagat Pharma Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Chandra Bhagat Pharma's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Chandra Bhagat Pharma (BOM:542934) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chandra Bhagat Pharma Ltd (BOM:542934) » Definitions » Debt-to-EBITDA

Traded in Other Exchanges

N/A

Address

Doctor Ambedkar Road, 323-F Bhagat Bhuvan, Matunga (East), Mumbai, MH, IND, 400019

Website

https://www.cbcpharma.com

Chandra Bhagat Pharma Ltd is engaged in the business of marketing pharmaceutical critical care and health care products. The company provides a pharmaceutical formulation in therapeutic categories for formulations such as Anti-cancer (Oncology), Antibiotics, Anesthesia, Hormones, Orthopedic, Cardiac, Cardiovascular, Anti-fungal, Antiviral, Pediatrics, Cardiology, Nephrology, Neurology, and others. It is also engaged in promoting and marketing Active Pharmaceuticals Ingredients (APIs) in India.

Chandra Bhagat Pharma (BOM:542934) Headlines

No Headlines